Clinical Trial Update: Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 trial of belantamab mafodotin as maintenance therapy after salvage autologous hematopoietic cell transplantation in relapse/refractory multiple myelom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab mafodotin (Blenrep) (belantamab mafodotin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Multiple Myeloma | Phase 1 | Status: TERMINATED